Abstracts
PO77
Clinical Profile and Treatment Outcomes of Adult Hodgkin Lymphoma: A Retrospective Cohort Study from A Philippine Tertiary Care Institution
Introduction/Background/Significance:
Materials and Methods/Case Presentation/Objective: This retrospective cohort study included adults (≥19 years) diagnosed with HL from January 2021 to December 2025. Clinical, laboratory, treatment, and outcome data were extracted from medical records. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier analysis, and prognostic factors were evaluated using Cox regression.
Results/Description/Main Outcome Measure(s): Seventy-three patients were included. Most were < 45 years (97.3%), female (53.4%), and presented with advanced-stage disease (71.2%), bulky disease (72.6%), and B symptoms (60.3%). Nodular sclerosis was the predominant subtype (78.1%). ABVD-based regimens were the most common first-line treatment (57.5%). Complete remission was achieved in 42.5%, while 50.7% developed progressive disease. Five-year OS and PFS were approximately 75%, with median survival not reached. Age < 45 years was the only significant predictor of OS (HR 17.9, p=0.013). Overall, 26.0% required second-line therapy and 16.4% were referred for hematopoietic stem cell transplantation.
Conclusion(s).: Adult HL patients in this cohort commonly presented with advanced disease and had modest remission rates. Despite relatively favorable survival, a substantial proportion required multiple lines of therapy. Early detection, risk-adapted treatment, and improved access to advanced therapies are essential to improve outcomes.
Trademarked Items:
References:
Hodgkin lymphoma (HL) is a highly curable malignancy, but outcomes in low- and middle-income countries may be affected by delayed diagnosis and limited access to care. Data on adult HL in the Philippines remain scarce. This study described the clinical characteristics, treatment patterns, and outcomes of adult HL patients in a tertiary care institution.
Materials and Methods/Case Presentation/Objective: This retrospective cohort study included adults (≥19 years) diagnosed with HL from January 2021 to December 2025. Clinical, laboratory, treatment, and outcome data were extracted from medical records. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier analysis, and prognostic factors were evaluated using Cox regression.
Results/Description/Main Outcome Measure(s): Seventy-three patients were included. Most were < 45 years (97.3%), female (53.4%), and presented with advanced-stage disease (71.2%), bulky disease (72.6%), and B symptoms (60.3%). Nodular sclerosis was the predominant subtype (78.1%). ABVD-based regimens were the most common first-line treatment (57.5%). Complete remission was achieved in 42.5%, while 50.7% developed progressive disease. Five-year OS and PFS were approximately 75%, with median survival not reached. Age < 45 years was the only significant predictor of OS (HR 17.9, p=0.013). Overall, 26.0% required second-line therapy and 16.4% were referred for hematopoietic stem cell transplantation.
Conclusion(s).: Adult HL patients in this cohort commonly presented with advanced disease and had modest remission rates. Despite relatively favorable survival, a substantial proportion required multiple lines of therapy. Early detection, risk-adapted treatment, and improved access to advanced therapies are essential to improve outcomes.
Trademarked Items:
References:
